Table 2.
Subgroup analyses regarding the pooled recovery rates (%) at 1, 3, and 6 months.
| Subgroup | Rate (95% CI) | ||
|---|---|---|---|
| 1 month | 3 months | 6 months | |
| Treatment types | |||
| Nonspecific treatment | 46.2 (35.5–57.3)* | 72.5 (48.7–88.1) | 87.6 (83.4–90.8) |
| Specific treatment | 71.9 (61.7–80.3) | 81.5 (71.0–88.8) | 85.2 (74.7–91.9) |
| Patient types | |||
| Inpatient | 70.5 (63.5–76.6) | 77.6 (51.9–91.8) | 82.1 (64.3–92.1) |
| Outpatient | 64.5 (49.2–77.3) | 71.2 (62.0–80.8) | 87.8 (83.9–90.8) |
| Diagnostic age | |||
| ≥18 months | 77.8 (66.1–86.3) | 88.2 (68.1–96.3) | 83.5 (65.5–93.1) |
| <18 months | 74.7 (60.8–84.9) | 76.5 (62.0–86.6) | 87.4 (79.8–92.4) |
| Duration of exposure | |||
| ≥12 months | 81.2 (62.8–91.8) | 71.7 (52.8–85.2) | 79.9 (48.2–94.4) |
| <12 months | 71.2 (59.8–80.4) | 68.2 (46.6–84.0) | 87.5 (80.7–92.1) |
*P value for test of heterogeneity between subgroup estimates was <0.001; all other P values for test of heterogeneity were >0.05.